Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy
Information source: Yonsei University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Chronic Hepatitis B
Intervention: Switching from adefovir (10mg/day) to tenofovir (300mg/day) (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Yonsei University Official(s) and/or principal investigator(s): Sang Hoon Ahn, MD, PhD., Principal Investigator, Affiliation: Department of Internal Medicine, Yonsei University College of Medicine
Overall contact: BeomKyung Kim, Dr., Phone: 82-2-2228-1930, Email: beomkkim@yuhs.ac
Summary
In Korea, the number of suboptimal responders to rescue combination therapy is also
increasing. As a matter of fact, according to the investigations in Korea, HBV DNA
undetectability at 48 weeks of adefovir and lamivudine combination rescue therapy for
patients with lamivudine resistance was reported to be only 32. 4%, which suggested that the
appropriate another rescue therapy might be urgently required. However, there is no
promising oral antiviral agents to control these patients in Asia-Pacific region, where
tenofovir is not widely available. Tenofovir has a higher potent antiviral efficacy and a
negligible drug resistance rate. The switch from adefovir to tenofovir in patients who have
insufficient hepatitis B virus (HBV) suppression (HBV DNA ≥ 60 IU/mL by PCR) may lead to
increased viral suppression or more HBeAg loss/seroconversion.
Here, the investigators aimed to conduct a randomized study on evaluating the antiviral
efficacy, safety, and tolerability of switching from adefovir to tenofovir in chronic
hepatitis B patients who have suboptimal response to adefovir-based combination rescue
therapy due to nucleoside analogues Resistance (SATIS study).
Clinical Details
Official title: Randomized Study Comparing Nucleoside Analogues Plus Tenofovir and Nucleoside Analogues Plus Adefovir in Chronic Hepatitis B Patients With Suboptimal Response to Adefovir-based Combination Therapy Due to Nucleoside Analogues Resistance
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: number of patients with complete virologic response (HBV DNA < 60 IU/mL, approximately 300 copies/mL) at 48 weeks treatment
Secondary outcome: number of patients with antiviral response at 48 weeks therapynumber of patients with biochemical response at 48 weeks therapy number of patients with serologic response at 48 weeks therapy number of patients with appearance of resistant mutant strain at 48 weeks Number of Participants with Adverse Events
Detailed description:
The major goal of antiviral therapy against chronic hepatitis B is to suppress viral
replications successfully, ultimately preventing the chronic liver damage, development of
liver cirrhosis and hepatocellular carcinoma. In Korea, the number of multi-drug resistant
CHB has been rapidly increased last few years. It is because that the national health
insurance coverage is very limited for the patients who experienced primary treatment
failure. The only switch to adefovir has been allowed in lamivudine resistant patients and
thus this sequential rescue therapy generated multi-drug resistance to both adefovir and
another drugs. Thus, nowadays, add-on therapy rather than switch therapy might be preferred
from major guidelines in this point.
However, the number of suboptimal responders to rescue combination therapy is also
increasing. As a matter of fact, according to the investigations in Korea, HBV DNA
undetectability at 48 weeks of adefovir and lamivudine combination rescue therapy for
patients with lamivudine resistance was reported to be only 32. 4%, which suggested that the
appropriate another rescue therapy might be urgently required. However, there is no
promising oral antiviral agents to control these patients in Asia-Pacific region, where
tenofovir is not widely available. Tenofovir has a higher potent antiviral efficacy and a
negligible drug resistance rate. It belongs to the different class compared to other oral
nucleoside analogues (NAs) such as lamivudine, telbivudine, clevudine and entecavir. The
switch from adefovir to tenofovir in patients who have insufficient hepatitis B virus (HBV)
suppression (HBV DNA ≥ 60 IU/mL by PCR) may lead to increased viral suppression or more
HBeAg loss/seroconversion. The results of this study will provide a rationale for switch
from adefovir to tenofovir in combination to another drug continued (lamivudine,
telbivudine, clevudine and entecavir).
Here, the investigators aimed to conduct a randomized study on evaluating the antiviral
efficacy, safety, and tolerability of switching from adefovir to tenofovir in chronic
hepatitis B patients who have suboptimal response to adefovir-based combination rescue
therapy due to nucleoside analogues Resistance (SATIS study).
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- subjects with age >= 20 years
- subjects with chronic hepatitis B
- subjects treated with nucleoside analogues plus adefovir for at least 6 months due to
resistance to nucleoside analogues (Lamivudine, Telbivudine, Entecavir, or Clevudine)
- subjects with partial virologic response to nucleoside analogues plus adefovir HBV
DNA ≥ 60 IU/mL)
- subjects with ALT less than 5 times of upper limit of normal
- subjects who agreed to participate in the clinical trials and signed the informed
consents
Exclusion Criteria:
- subjects with decompensate liver cirrhosis Child-Pugh B, C)
- subjects with Adefovir mutation
- subjects with HCV, HDV, or HIV infection
- pregnant or lactating women
- women of childbearing age who do not use the appropriate contraception method
- subjects who have the abnormal lesion suspected of hepatocellular carcinoma on
imaging modalities
- subjects with other liver diseases such as hemochromatosis, Wilson's disease,
alcoholic liver disease, nonalcoholic liver disease, alpha-1 antitrypsin deficiency
- subjects with hypersensitivity for study drugs
- subjects who participated in other clinical trials 60 days before the current
recruitment
- subjects who are judged as inappropriate by investigators
Locations and Contacts
BeomKyung Kim, Dr., Phone: 82-2-2228-1930, Email: beomkkim@yuhs.ac
Department of Internal Medicine, Yonsei University College of Medicine, Seoul 120-752, Korea, Republic of; Recruiting BeomKyung Kim, Dr, Phone: +82-2-2228-1930, Email: beomkkim@yuhs.ac Jun Yong Park, Dr, Phone: +82-2-2228-1994, Email: DRPJY@yuhs.ac
Additional Information
Starting date: March 2012
Last updated: May 9, 2012
|